Our top pick for
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Capricor Therapeutics, Inc is a biotechnology business based in the US. Capricor Therapeutics shares (CAPR) are listed on the NASDAQ and all prices are listed in US Dollars. Capricor Therapeutics employs 16 staff and has a trailing 12-month revenue of around USD$474,520.
Since the stock market crash in March caused by coronavirus, Capricor Therapeutics's share price has had significant positive movement.
Its last market close was USD$4.63, which is 69.98% up on its pre-crash value of USD$1.39 and 426.14% up on the lowest point reached during the March crash when the shares fell as low as USD$0.88.
If you had bought USD$1,000 worth of Capricor Therapeutics shares at the start of February 2020, those shares would have been worth USD$773.34 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth USD$3,086.68.
|Latest market close||USD$4.63|
|52-week range||USD$0.88 - USD$12.32|
|50-day moving average||USD$4.5881|
|200-day moving average||USD$5.3964|
|Wall St. target price||USD$10.5|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-3.736|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2020-11-18)||4.75%|
|1 month (2020-10-23)||3.58%|
|3 months (2020-08-25)||-18.91%|
|6 months (2020-05-22)||-14.10%|
|1 year (2019-11-25)||151.63%|
|2 years (2018-11-23)||451.19%|
|3 years (2017-11-24)||120.48%|
|5 years (2015-11-25)||0.65%|
|Gross profit TTM||USD$-4,136,777|
|Return on assets TTM||-31.16%|
|Return on equity TTM||-64.44%|
|Market capitalisation||USD$87.3 million|
TTM: trailing 12 months
There are currently 1.2 million Capricor Therapeutics shares held short by investors – that's known as Capricor Therapeutics's "short interest". This figure is 10% down from 1.3 million last month.
There are a few different ways that this level of interest in shorting Capricor Therapeutics shares can be evaluated.
Capricor Therapeutics's "short interest ratio" (SIR) is the quantity of Capricor Therapeutics shares currently shorted divided by the average quantity of Capricor Therapeutics shares traded daily (recently around 429724.90974729). Capricor Therapeutics's SIR currently stands at 2.77. In other words for every 100,000 Capricor Therapeutics shares traded daily on the market, roughly 2770 shares are currently held short.
However Capricor Therapeutics's short interest can also be evaluated against the total number of Capricor Therapeutics shares, or, against the total number of tradable Capricor Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Capricor Therapeutics's short interest could be expressed as 0.06% of the outstanding shares (for every 100,000 Capricor Therapeutics shares in existence, roughly 60 shares are currently held short) or 0.0619% of the tradable shares (for every 100,000 tradable Capricor Therapeutics shares, roughly 62 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Capricor Therapeutics.
Find out more about how you can short Capricor Therapeutics stock.
We're not expecting Capricor Therapeutics to pay a dividend over the next 12 months.
Capricor Therapeutics's shares were split on a 1:10 basis on 5 June 2019. So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Capricor Therapeutics shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for Capricor Therapeutics shares which in turn could have impacted Capricor Therapeutics's share price.
Over the last 12 months, Capricor Therapeutics's shares have ranged in value from as little as $0.88 up to $12.32. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Capricor Therapeutics's is 7.3303. This would suggest that Capricor Therapeutics's shares are significantly more volatile than the average for this exchange and represent a higher risk.
Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of biological therapies for the treatment of diseases, with a focus on Duchenne muscular dystrophy (DMD), and other rare disorders. The company's development stage drug candidates for cardiosphere-derived cells include CAP-1002, a cardiac cell derived therapy, which is in phase II clinical trial for the treatment of patients with late-stage DMD; and completed various trials investigating the use of CAP-1002 for the treatment of cardiac conditions, including heart failure and post myocardial infarction with cardiac dysfunction. It is also developing CAP-2003 that is in pre-clinical development for the treatment of inflammatory conditions. The company was founded in 2005 and is headquartered in Beverly Hills, California.
Everything we know about the NewRez IPO, plus information on how to buy in.
Everything we know about the Perella Weinberg IPO, plus information on how to buy in.
Everything we know about the Nanobiotix IPO, plus information on how to buy in.
Everything we know about the Diversey IPO, plus information on how to buy in.
Everything we know about the Certara IPO, plus information on how to buy in.
Everything we know about the Arrival IPO, plus information on how to buy in.
Everything we know about the iSpecimen IPO, plus information on how to buy in.
Everything we know about the IDEX Biometrics ASA IPO, plus information on how to buy in.
Steps to owning and managing MYSZ, with 24-hour and historical pricing before you buy.
Steps to owning and managing MG, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.